279 related articles for article (PubMed ID: 31002529)
1. Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Morgan MM; Arendt LM; Alarid ET; Beebe DJ; Johnson BP
FASEB J; 2019 Jul; 33(7):8623-8633. PubMed ID: 31002529
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
3. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.
Strong AL; Ohlstein JF; Biagas BA; Rhodes LV; Pei DT; Tucker HA; Llamas C; Bowles AC; Dutreil MF; Zhang S; Gimble JM; Burow ME; Bunnell BA
Breast Cancer Res; 2015 Aug; 17(1):112. PubMed ID: 26286584
[TBL] [Abstract][Full Text] [Related]
4. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Yamaguchi Y; Takei H; Suemasu K; Kobayashi Y; Kurosumi M; Harada N; Hayashi S
Cancer Res; 2005 Jun; 65(11):4653-62. PubMed ID: 15930283
[TBL] [Abstract][Full Text] [Related]
5. Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
Amanatullah DF; Tamaresis JS; Chu P; Bachmann MH; Hoang NM; Collyar D; Mayer AT; West RB; Maloney WJ; Contag CH; King BL
Breast Cancer Res; 2017 Nov; 19(1):121. PubMed ID: 29141657
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
[TBL] [Abstract][Full Text] [Related]
7. Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways.
Strong AL; Strong TA; Rhodes LV; Semon JA; Zhang X; Shi Z; Zhang S; Gimble JM; Burow ME; Bunnell BA
Breast Cancer Res; 2013; 15(5):R102. PubMed ID: 24176089
[TBL] [Abstract][Full Text] [Related]
8. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
9. Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model.
Morgan MM; Livingston MK; Warrick JW; Stanek EM; Alarid ET; Beebe DJ; Johnson BP
Sci Rep; 2018 May; 8(1):7139. PubMed ID: 29740030
[TBL] [Abstract][Full Text] [Related]
10. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
11. Estrogen metabolites and breast cancer.
Santen RJ; Yue W; Wang JP
Steroids; 2015 Jul; 99(Pt A):61-6. PubMed ID: 25168343
[TBL] [Abstract][Full Text] [Related]
12. Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Heneweer M; Muusse M; Dingemans M; de Jong PC; van den Berg M; Sanderson JT
Toxicol Sci; 2005 Feb; 83(2):257-63. PubMed ID: 15525692
[TBL] [Abstract][Full Text] [Related]
13. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
15. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors and their antitumor effects in model systems.
Brodie A; Lu Q; Liu Y; Long B
Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
[TBL] [Abstract][Full Text] [Related]
17. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
18. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
19. Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.
Bhardwaj P; Au CC; Benito-Martin A; Ladumor H; Oshchepkova S; Moges R; Brown KA
J Steroid Biochem Mol Biol; 2019 May; 189():161-170. PubMed ID: 30851382
[TBL] [Abstract][Full Text] [Related]
20. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
